HEARSTHEALTH
international

FDB OptimiseRx:

Complex Cost Messages

INTENTION OF MESSAGE

Complex Cost messages present the prescriber with a list of lower cost alternative drug products which may be the same drug at a different strength, dose and/or formulation or a therapeutically equivalent (e.g. from felodipine to amlodipine) drug product. These messages may also include additional national best practice guidance for the prescriber to consider. Where there are multiple alternative products a complex cost message will be used instead of a Simple Cost Message.

SOURCES REFERENCED

Annual Prescription Cost Analysis data (for per patient per year savings), NHS Dictionary of Medicines and Devices (dm+d), Price concessions (NCSO), and local sources.

MESSAGE CRITERIA

Complex Cost messages will trigger once an applicable drug product has been chosen by the prescriber and a complex cost alternative drug product is available. These messages may also include additional logic (e.g. to identify patient specific context) that must be met for the message to trigger. This ensures that the swap is only presented only where relevant.

Message logic may consider documented past medical history, previously prescribed drug products and patient specific criteria. The message will explain the rationale (and applicable references) for presenting therapeutically interchangeable products and provide alternative drug products for the prescriber to select from.

WORKFLOW: ACUTE PRESCRIPTIONS

Complex Cost Swap messages will appear to the prescriber once a drug product has been selected (prior to a dose and supply quantity being defined) if the message logic is met.

These message types will also trigger on reauthorisation and restart if the criteria is met.

REPORTING

The performance of Complex Cost Messages can be monitored over time through Actualised Cost Savings or Financial Year Cost Savings Reports, available on the OptimiseRx Portal.

Cost savings for these messages are calculated as either 'per acute' or 'per patient per year'. Savings for drugs that are used for chronic treatments are calculated over the course of 1 year and these swaps will have a 'per patient per year' saving. Drugs that are used for acute or intermittent treatment have a calculated saving of 'per dose unit', e.g. tablet, capsule, spray etc.

In some cases, it is not possible to calculate a cost saving for complex swap messages. Savings can only be calculated for brands and drug tariff generics (except specials).

FDBOptimiseRx

FDB OptimiseRx: Complex Cost Messages

Example of a point of Complex Cost Message in EMIS Web



Example of a point of Complex Cost Message in SystmOne

HEARSTHEALTH international

HEARSTHEALTH
international

FDB OptimiseRx:

Simple Cost Messages

INTENTION OF MESSAGE

Simple Cost messages present the prescriber with a single lower cost alternative drug product of the same drug and strength.

The formulation of this alternative drug product may be slightly different, for example presenting a cheaper capsule formulation of a drug product originally ordered as tablets.

SOURCES REFERENCED

Drug Tariff, NHS Dictionary of Medicines and Devices (dm+d), price concessions and Generic Medicine Shortages (NCSO).

MESSAGE CRITERIA

Simple Cost Swap messages will trigger once prescription details have been completed and a cheaper alternative drug product is available. Cost savings for these messages are calculated based on the dosing information entered by the prescriber. These messages are one to one (i.e. one trigger product and one alternate product) with no additional patient specific filtering.

END-USER WORKFLOW: NEW PRESCRIPTIONS

Simple Cost Swap messages will appear to the prescriber once a drug product and supply quantity have been selected. The message will show the original and alternative drug product alongside each other together with the costs and calculated saving were the message to be accepted. These messages do not contain references or guidance to the prescriber.

These message types will also trigger on reauthorisation and restart if the criteria is met.

REPORTING

The performance of Simple Cost Messages can be monitored over time through Actualised Cost Savings or Financial Year Cost Savings Reports, available on the OptimiseRx Portal.

Cost savings for these messages are calculated as either 'per dose unit' or 'per patient per year'. Savings for drugs that are used for chronic treatments are calculated over the course of one year and these messages will have a 'per patient per year' saving. Drugs that are used for acute or intermittent treatment have a calculated saving of 'per dose unit', e.g. tablet, capsule, spray etc.

FDBOptimiseRx

FDB OptimiseRx: Simple Cost Messages



Example of a Simple Cost Swap Message in EMIS Web



Example of a Simple Cost Swap Message in SystmOne

HEARSTHEALTH
international

FDB OptimiseRx:

Solution Overview

AIMS OF MESSAGE

OptimiseRx messages enable you to deliver high value clinical guidance at the point of care. These messages should promote safe prescribing against best practice and where applicable provide alternative drug products and associated savings.

Messages are authored to make them as effective and meaningful to the prescriber as possible. To achieve this, all messages aim to be succinct, accurate and patient contextual. Wherever possible it is intended that messages be actionable by the prescriber as opposed alerting for information only.

GOAL ORIENTATED MESSAGES

Considering the desired prescribing outcomes when requesting messages ensures that OptimiseRx aligns with your wider medicines initiatives and helps in tailoring the OptimiseRx profile to maximise value.

MESSAGE SCOPE

Once the message requests align to prescribing initiatives the following criteria can be used to ensure that they are feasible and will provide value to the prescriber while helping to achieve prescribing goals.

INCLUDED

- Is the message related to the product that will trigger it?
- Is the rule patient contextual? Is the criterion (e.g. weight, age, past medication) being evaluated routinely and accurately documented within the Patient's electronic record using Read Code or dm+d terminology?
- Does the message provide a clear intervention for the prescriber to make?
  - This may include:
    - The stopping of a product and/or treatment regime
    - The amendment of a product and/or treatment regime, including but not limited to:
      - Cost swaps
      - Therapy changes or substitutions
      - The addition of product to a treatment regime (i.e. a concomitant prescription)*
    - The ordering or review of supplementary diagnostics
- Is a localised OptimiseRx message the best way for you to support the intended message outcome/guide the prescribers towards best practice?

FDBOptimiseRx

EXCLUDED

It's important that OptimiseRx messages provide value without interrupting users with ambiguous messages or duplicating or conflicting with any existing alerts. Answering 'No' to the below helps in avoiding this:

- Will the message overlap or interact with and existing Clinical Decision Support (CDS) without providing clearly defined additional value?
  - This may include:
    - Existing drug-drug interactions
    - Existing drug-allergy interactions
    - Existing drug-condition interactions
    - Existing OptimiseRx messages
- Does the message have the potential to cause alert fatigue by presenting for most prescriptions?
- Does the message only provide general information about the drug without any clear intervention for the prescriber to make?

Further information and guidance on how to request and author the most effective localised OptimiseRx messages can be provided by your Account Manager and Content Representatives.

VALUE & RETURN ON INVESTMENT

Message usage and adoption analysis should be carried out on a periodic basis to determine if messages are providing their expected value. Messages considered no longer relevant/useful should be reviewed for potential amendments or retirement.

*Please note this OptimiseRx functionality is only available within the SystmOne and Microtest system

HEARSTHEALTH
international

FDB OptimiseRx – Localising national messages:

Text & URLs functionality

Localise national messages within your core profile by adding references, text and URLs, eliminating the need for a new CCG localised message. The core national message components are authored and maintained by FDB OptimiseRx.

IDENTIFYING MESSAGES ELIGIBLE FOR CCG TEXT AND URLS IN YOUR PROFILE

- Add a specific local message
- Insert direct links to local guidance sources
- Core message components are maintained by the OptimiseRx Content Team

FDBOptimiseRx

CCG TEXT AND URL CAN BE EDITED & DELETED

WITH A FULL AUDIT HISTORY CAPTURING THE CHANGES

- Full audit history of changes
- Edit and delete content that you have added
- Blue icon identifies when a message has been edited

HEARSTHEALTH
international

FDB OptimiseRx Best Practice & Safety:

Do Not Prescribe Messages

INTENTION OF MESSAGE

Do Not Prescribe messages present the prescriber with a message providing localised guidance and national best practice guidance which indicates that the drug product in focus may not be appropriate to prescribe for the patient in context.

SOURCES REFERENCED

Nationally Triaged Sources, Local Sources.

MESSAGE CRITERIA

Do Not Prescribe messages will trigger once an applicable drug product has been selected and any additional logic in relation to patient specific context is met. Message logic can assess criteria such as documented patient specific medical history, previously prescribed drug products and patient specific parameters.

WORKFLOW: NEW PRESCRIPTIONS

Do Not Prescribe messages will appear once a product has been selected (prior to dose and supply quantity being defined) if the message logic is met.

Message logic can assess criteria such as documented medical history, previously prescribed products and patient specific criteria. The message will explain its rationale for firing and may include additional information on interventions. This message type cannot be accepted or rejected, only acknowledged.

These message types will also trigger on reauthorisation and restart if the criteria is met.

REPORTING

The performance of Do Not Prescribe Messages can be monitored over time through the Best Practice Message Metrics Report, available on the OptimiseRx Portal.

Accept and reject counts for these messages are taken from whether the message trigger drug product was or was not prescribed at the end of the consultation where the message displayed.

FDBOptimiseRx

FDB OptimiseRx - Best Practice & Safety: Do Not Prescribe Messages



Example of a point of care Best Practice & Safety Do Not Prescribe Message in EMIS Web



Example of a point of care Best Practice & Safety Do Not Prescribe Message in SystmOne

HEARSTHEALTH
international

FDB OptimiseRx:

Formulary Messages

(Also known as RAG or Traffic Light Messages)

INTENTION OF MESSAGE

Formulary Messages notify the prescriber whether the drug product being prescribed is on a CCG restricted list (most commonly 'amber' or 'red') and provide additional guidance provided by local guidance (e.g. only prescribe under specialist supervision, do not prescribe). These messages are information only and do not provide alternative drug products.

SOURCES REFERENCED

Local Formularies.

MESSAGE CRITERIA

Formulary messages will trigger once an applicable drug product has been selected and it appears on a formulary list.

Messages can also be condition specific, meaning that an alert will only be presented if a drug is/is not being prescribed for a documented indication.

As a localised formulary feature, you have control over the message criteria.

WORKFLOW: NEW PRESCRIPTIONS

Formulary messages will appear once a drug product has been selected (prior to dose and supply quantity being defined) if the message logic is met. Message logic may include patient specific medical history for indication specific formulary messages.

The message will explain its rationale for presenting and allow the prescriber to acknowledge the message, after which they can either continue or stop prescribing the drug product. 'Amber' messages (or other colour indicating shared care) will be authored to only fire at initial prescribing whereas 'red' messages will fire whenever a 'red' product is prescribed or reauthorised. A link to local formulary guidance will be provided within a Formulary Message.

REPORTING

The performance of Formulary Messages can be monitored over time through the Formulary Message Metrics Report, available on the OptimiseRx Portal.

FDBOptimiseRx

FDB OptimiseRx: Formulary Messages



Example of a point of care 'Red' Formulary Message in EMIS Web

Example of a point of care 'Red' Formulary Message in SystmOne

HEARSTHEALTH
international

HEARSTHEALTH
international

FDB OptimiseRx Best Practice & Safety:

Information Only Messages

INTENTION OF MESSAGE

Information Only messages present the prescriber with an informational message promoting an intervention or consideration relating to the drug product being prescribed. This message cannot be accepted or rejected as any intervention is intended to be made outside of the prescribing workflow.

SOURCES REFERENCED

Nationally Triaged Sources, Local Sources.

MESSAGE CRITERIA

Information Only messages will be presented once an applicable drug product has been selected and any additional logic in relation to patient context is met. Message logic can assess criteria such as documented patient specific medical history, previously prescribed drug products and patient specific parameters.

WORKFLOW: NEW PRESCRIPTIONS

Information Only messages will appear once a drug product has been selected (prior to dose and supply quantity being defined) if the message logic is met.

The message will explain its rationale for firing along with the potential interventions. This message type can only be acknowledged by a prescriber who can then continue with their existing prescription.

These message types will also trigger on reauthorisation and restart if the criteria are met.

REPORTING

The performance of Information Only Best Practice Messages can be monitored over time through the Information Only Messages Report, available on the OptimiseRx Portal.

FDBOptimiseRx

FDB OptimiseRx - Best Practice & Safety: Information Only Messages



Example of a point of a Best Practice & Safety Information Only Message in EMIS Web



Example of a point of a Best Practice & Safety Information Only Message in SystmOne

HEARSTHEALTH international

HEARST HEALTH international

FDB OptimiseRx Best Practice & Safety:

Prescribable Alternative Products

INTENTION OF MESSAGE

Prescribable Alternative Product Best Practice and Safety messages present the prescriber with national best practice guidance and localised clinical guidance relating to the drug product being prescribed and patient in context. This message can be acted on (accepted or rejected) and an alternative drug product selected to be prescribed within the workflow.

SOURCES REFERENCED

Nationally Triaged Sources, Local Sources.

MESSAGE CRITERIA

Prescribable Alternative Product Best Practice and Safety messages will trigger once an applicable product has been selected and any additional message logic in relation to patient specific context is met. Message logic can assess criteria such as documented patient specific medical history, previously prescribed drug product and patient specific parameters. The message will explain its rationale for firing along with the intervention that can be made.

END-USER WORKFLOW: NEW PRESCRIPTIONS

Alternative Product Best Practice and Safety messages will appear to the prescriber once a drug product has been selected (prior to a dose and supply quantity being defined) if the message logic is met. Prescribers can accept or reject this message.

These message types will also trigger on reauthorisation and restart if the criteria are met.

REPORTING

The performance of Alternative Product Best Practice Messages can be monitored over time through the Best Practice Message Metrics Report, available on the OptimiseRx Portal.

FDBOptimiseRx

FDB OptimiseRx - Best Practice & Safety: Prescribable Alternative Products



Example of a point of care Best Practice & Safety Actionable Message in Emis Web

Example of a point of care Best Practice & Safety Actionable Message in SystmOne

HEARSTHEALTH international

HEARSTHEALTH international

FDB OptimiseRx:

Best Practice Sources

The OptimiseRx content team routinely evaluate multiple national best practice sources for content to be authored into OptimiseRx messages.

DRUG SAFETY ALERTS (MHRA)

Medicines and Healthcare Products Regulatory Agency (MHRA) Drug safety alerts are reviewed for possible inclusion in OptimiseRx.

INCLUDED

Alerts from the MHRA affecting drugs prescribed in primary care that OptimiseRx logic can support are authored.

EXCLUDED

Where there is no additional value over the prescribing decision support already present in clinical systems. Safety alerts relating to drugs used only in secondary care, United States Food and Drug Administration (FDA) warnings or non-UK source alerts (except for European Medicines Agency) and alerts relating to devices and field safety notices are also excluded.

PUBLIC HEALTH ENGLAND

Antimicrobial Public Health England (PHE) guidance is currently monitored for inclusion in OptimiseRx. All other PHE guidance is not actively reviewed for inclusion however may be considered on customer request.

PRESCQIPP

All publicly available PrescQIPP bulletins are reviewed for inclusion in OptimiseRx.

NICE GUIDANCE

NICE Guidance related to the below core long term conditions are reviewed on release for potential messages to be included in OptimiseRx:

CORE THERAPEUTIC TOPICS

- Diabetes
- Ischaemic heart disease
- Heart failure
- Hypertension
- Chronic Kidney Disease
- Chronic Obstructive Pulmonary Disease

FDBOptimiseRx

FDB OptimiseRx: Best Practice Sources

NICE KEY THERAPEUTIC TOPICS

All NICE KTTs (published on an annual basis) are reviewed for potential addition of OptimiseRx messages.

NHS ENGLAND

NHS England is monitored and guidance related to NHS England funded and recommended medications is reflected in OptimiseRx messages.

OTHER SOURCES

The below sources are also monitored periodically for any relevant information that may affect existing messages:

- SPC updates (e.g. changes to indications/licensing that may affect existing messages)
- Drug Tariff (Borderline substances)
- Ophthalmic Specials
- Prescribing indicators:
  - Royal College of GPs revalidation safety prescribing indicators
  - Beers criteria
  - STOPP criteria
  - PINCER

HEARSTHEALTH international

HEARSTHEALTH international

FDB OptimiseRx:

Working alongside existing Clinical Decision Support

AIMS OF MESSAGE

OptimiseRx messages enable you to deliver high value clinical guidance at the point of care. All messages aim to be succinct, accurate and patient contextual to avoid prescriber alert fatigue and/or possible confusion.

OptimiseRx messages need to be complimentary to the presence of alerts in clinical systems and avoid any potential to duplicate or overlap with these.

To achieve this, OptimiseRx messages should not directly overlap or interact with a clinical system's existing Clinical Decision Support (CDS).

OptimiseRx may include messages that are also present in a clinical system's prescribing decision support where OptimiseRx can offer CCGs and prescribers additional value over and above what is offered in existing CDS. This ensures that OptimiseRx never directly duplicates existing CDS present in clinical systems and ensures that the use of OptimiseRx is consistent across these clinical systems. Where a message is unable to be activated in EMIS Web it will be denoted in the OptimiseRx portal by the e symbol:

STEP 1: SAFETY SOURCES

National best practice guidance issued by the below authoritative sources are routinely reviewed for possible messages:

- MHRA Drug Safety Alerts
- Royal College of GPs revalidation safety prescribing indicators
- NICE Guidance & Key Therapeutic Topics

Additionally, customer message requests may occasionally overlap with existing CDS provided in the clinical system. These items are appraised by the FDB editorial team who will consider the addition of these messages based on the additional value OptimiseRx may be able to offer.

FDBOptimiseRx

STEP 2: ADDITIONAL VALUE

Where message requests conflict or overlap with a clinical system's existing CDS, the OptimiseRx message must provide additional value to the prescriber. Additional value can be defined as either:

ADDITIONAL PATIENT SPECIFICITY

The OptimiseRx message must contain patient criteria additional to what is used by existing CDS and therefore limiting the presentation of the message to a defined set of specific patient scenarios. This additional patient specificity means messages will present in specific circumstances only; this is not the case if the modification is only present in the text of the message and not something that can be coded against to avoid excessive alerting.

PROVIDING A PRESCRIBABLE ALTERNATIVE PRODUCT

Navigating to alternative drug products makes it easier for prescribers to adhere to guidance and therefore gain greater benefit from OptimiseRx compared to a clinical system's existing CDS. Where an appropriate alternative drug product has been proposed by a CCG or in national best practice guidance consideration will be given to authoring an OptimiseRx message that may otherwise directly conflict or overlap with the clinical system's CDS.

*Please note this OptimiseRx functionality is only available within the SystmOne and Microtest system

HEARSTHEALTH international